Nutra Pharma Corp under the ticker symbol NPHC. Here is some more information that we have about Nutra Pharma Corp

Get our alerts and future stock picks in your email inbox

Nutra Pharma Corp
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma Corporation, through its subsidiary, ReceptoPharm, engages in the development of Cobroxin, Nyloxin OTC, and Nyloxin Rx for the treatment of moderate to severe chronic pain; RPI-78M for the treatment of neurological diseases, including Multiple Sclerosis, Adrenomyeloneuropathy, Amyotrophic Lateral Sclerosis, and Myasthenia Gravis; and RPI-MN for the treatment of viral diseases comprising HIV/AIDS and herpes. ReceptoPharm also provides contract research services through its ISO class 5 and good manufacturing practice certified facilities to third-party biotechnology and pharmaceutical companies. In addition, the company, through its other subsidiary, Designer Diagnostics, involves in the research, development, and sale of diagnostic test kits used for the rapid identification of infectious diseases, such as Nontuberculous Mycobacteria. Nutra Pharma Corporation continues to identify intellectual property and companies in the biotechnology arena. The company was founded in 2000 and is based in Coral Springs, Florida.
5 Employees
Last Reported Date: 04/13/15
Founded in 2000
Last $0.0033 USD
Change Today -0.0005 / -13.16%
Volume 267.0K
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

nutra pharma corp (NPHC) Snapshot

Open
$0.0038
Previous Close
$0.0038
Day High
$0.0038
Day Low
$0.0033
52 Week High
06/23/14 - $0.02
52 Week Low
03/31/15 - $0.0025
Market Cap
4.9M
Average Volume 10 Days
2.0M
EPS TTM
$-0.0013
Shares Outstanding
1.5B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Request Investor Kit
NPHC:US Advanced Stock Chart

Related News

No related news articles were found.

nutra pharma corp (NPHC) Related News

No Related News Found

nutra pharma corp (NPHC) Key Developments

Nutra Pharma Corporation announced delayed annual 10-K filing

On 04/01/2015, Nutra Pharma Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.

Nutra Pharma Corporation, Annual General Meeting, Apr 20, 2015

Nutra Pharma Corporation, Annual General Meeting, Apr 20, 2015., at 10:00 US Eastern Standard Time. Location: 12502 West Atlantic Blvd. Agenda: To approve a 1 for 40 reverse stock split of its issued and outstanding shares of common stock; and to transact such other business as may properly come before the special meeting or any adjournment thereof.

Nutra Pharma Announces Manufacturing Release of Pet Pain Away and Delivery of Initial Orders

Nutra Pharma Corp. announced that they have received their first manufacturing run of their homeopathic treatment for chronic pain in companion animals, Pet Pain-Away™. The company also announced that they have begun shipping and many distributors have already received their first orders. Pet Pain-Away™ is a homeopathic, non-narcotic, non-addictive, over-the-counter pain reliever. The product is primarily aimed at treating moderate to severe chronic pain in companion animals. It is specifically indicated to treat pain from hip dysplasia, arthritis pain, joint pain, and general chronic pain in dogs, cats and horses. Specialized proteins in Pet Pain-Away block the action of acetylcholine, a major stimulating neurotransmitter in the nervous system and activator of the inflammatory pathways. As a result, the pain and inflammation pathways are temporarily shut off.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NPHC:US $0.00 USD -0.0005

NPHC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $167.91 USD -1.26
Bayer AG €135.20 EUR +0.435
Biogen Inc $401.71 USD -28.57
Roche Holding AG SFr.276.60 CHF -2.30
 

Industry Analysis

NPHC

Industry Average

Valuation NPHC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Nutra Pharma Announces Manufacturing Release of Pet Pain-Away and Delivery of Initial Orders
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , announced today that they have received their first manufacturing run ...
  Read More...
Nutra Pharma Letter to Shareholders
[Marketwired] - Nutra Pharma Corporation , a biotechnology company that is developing treatments for Multiple Sclerosis , Human Immunodeficiency Virus , Adrenomyeloneuropathy and Pain, announced today that the Company's ...
  Read More...
NUTRA PHARMA CORP Financials
  Read More...
10-Q for Nutra Pharma Corp.
  Read More...
NUTRA PHARMA CORP Files SEC form 10-Q, Quarterly Report
  Read More...
Nutra Pharma Announces Laboratory Recertification and Manufacturing Updates
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , is announcing the recertification of their Plantation, Florida laboratory ...
  Read More...
Nutra Pharma Retains BUYINS.NET to Surveil Short Sellers and Market-Makers
[Marketwired] - Nutra Pharma Corp
  Read More...
Nutra Pharma Provides Nyloxin(R) Marketing Updates
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , is announcing updates to the marketing plan for their over-the-counter ...
  Read More...
NUTRA PHARMA CORP Files SEC form 10-Q/A, Quarterly Report
  Read More...
Nutra Pharma Announces Nyloxin Television Commercial Rollout
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , is announcing that MyNyloxin.com, a company that has the exclusive rights ...
  Read More...
Nutra Pharma Announces Completion of Commercials by MyNyloxin.com
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , is announcing that MyNyloxin.com, a new company that has the exclusive ...
  Read More...
Nutra Pharma Announces Contracts for Nyloxin Television Commercials
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , is announcing that MyNyloxin.com, a new company that has the exclusive ...
  Read More...
10-K for Nutra Pharma Corp.
  Read More...
Nutra Pharma to Seek GSA Certification, Will Market Military Strength Nyloxin to Governmental Agencies and the DoD
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , is announcing that they are seeking GSA Certification in order to supply ...
  Read More...
Nutra Pharma Announces Nyloxin(R) Distribution Plans for China
[Marketwired] - Nutra Pharma Corporation , a biotechnology company that is developing treatments for Multiple Sclerosis , Human Immunodeficiency Virus , Adrenomyeloneuropathy and Pain, announced today that they have engaged ...
  Read More...
NUTRA PHARMA CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
  Read More...
Nutra Pharma Provides Updates on Marketing and Distribution of Nyloxin(R) to India
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , is providing an update regarding their plan to market their over-the-counter ...
  Read More...
Nutra Pharma Announces New Telemarketing and Social Media Campaign Through MyNyloxin.com
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , is announcing that MyNyloxin.com, a new company that has the exclusive ...
  Read More...
NUTRA PHARMA CORP Files SEC form 10-K, Annual Report
  Read More...
Chairman & CEO Rik J. Deitsch of Nutra Pharma Corporation to Be Interviewed Live on iHeart Radio / Clear Channel Atlanta Studios - 640 WGST AM's "Health Tech Talk Live"
[Marketwired] - Nutra Pharma Corporation , a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, ...
  Read More...